Autoimmune Medical News by Date |
|
|
| March 2009 |
| Risks of myeloid malignancies in patients with autoimmune conditions. Medications used to treat autoimmune conditions, shared genetic predisposition and/or direct infiltration of bone marrow by autoimmune conditions, could explain these excess risks of myeloid malignancies. L.A. Anderson. British Journal of Cancer. March 3, 2009. (Also see: Myeloma (Bone Marrow Cancer)) |
| A Case of Autoimmune-Related Retinopathy and Optic Neuropathy (ARRON) Syndrome Treated by Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation. This report suggests that autologous HSCT may have a therapeutic role in ARRON syndrome. O. Yu, MD. Journal of Neuro-Opthamology.Volume 29(1)March 2009pp 43-49. (Also see: Retinal Involvement) |
| Cumulative Childhood Stress and Autoimmune Diseases in Adults. Childhood traumatic stress increased the likelihood of hospitalization with a diagnosed autoimmune disease decades into adulthood. S. Dube, PhD. Psychosomatic Medicine 71:243-250 (February 2009). (Also see: Stress and Disease and Autoimmunity) |
| Association between depression and coronary artery calcification (CAC) in women with systemic lupus erythematosus (SLE). In women with SLE, depression was associated with CAC, thus contributing to cardiovascular disease risk. C. Greco. Rheumatology. March 13, 2009. (Also see: Lupus and Heart Disease) |
| Time of initial appearance of renal symptoms in the course of systemic lupus erythematosus (SLE) as a prognostic factor for lupus nephritis (LN). Onset time of LN in the course of SLE may affect renal prognosis. (SpringerLink) Y. Takahashi. Modern Rheumatology. March 10, 2009. (Also see: Lupus and Kidney Involvement) |
| Intravenous lidocaine for fibromyalgia syndrome (FMS): an open trial. Intravenous lidocaine infusions are safe and effective in the management of FMS. (SpringerLink) M. Schafranski. Clinical Rheumatology. March 5, 2009. (Also see: FMS Treatments) |
| Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren's syndrome. IVIg might be an effective treatment for pain in Sjögren's syndrome-associated neuropathy. Further studies should be done in a controlled, blind study. Morozumi S. (PubMed) J Neurol Sci. 2009 Apr 15;279(1-2):57-61. 2009 Jan 24. (Also see: Neurological Involvement and Sjögren’s) |
| Chromosomal region 16p13: further evidence of increased predisposition to immune diseases. Our data evidence the influence of variants within this chromosomal region on the development of complex diseases. A. Martinez. Ann Rheum Dis. February 16, 2009. (Also see: Autoimmunity) |
| Hemolytic uremic syndrome (HUS) and pericarditis as early manifestations of primary Sjögren’s syndrome (pSS). We describe the unusual case of a pSS patient with the initial presentation of HUS and pericarditis and a fatal progression of pulmonary hemorrhage. (SpringerLink) Hung-An Chen. Clinical Rheumatology. March 5, 2009. (Also see: Sjogren's) |
| Liver fibrosis in patients with psoriasis and psoriatic arthritis (PsA) on long-term, high cumulative dose methotrexate therapy. Liver biopsy ought to be considered to assess the liver if liver function tests are persistently elevated. Pro-collagen 3 N-terminal peptide was unhelpful in PsA and frequently elevated despite normal liver biopsy. K. Lindsay. Rheumatology. March 9, 2009. (Also see: Psoriasis) |
| Leprosy Drug Holds Promise for Autoimmune Diseases. A century-old antibiotic used to treat leprosy may prove effective as a treatment for multiple sclerosis and other autoimmune diseases, Johns Hopkins researchers say. HealthDay News. February 4, 2009. (Also see: Treating Autoimmunity) |
| Are classification criteria for vasculitis useful in clinical practice? Observations and lessons from Colombia. Current vasculitis classification schemes are designed for classification, rather that diagnosis of disease and do not adequately address some common forms of inflammatory vascular diseases, including those of infectious etiology and unusual etiology seen in clinical practice. P. Patarroyo. Journal of Autoimmune Diseases. February 27, 2009. (Also see: Vasculitis) |
| The prevalence of obstructive sleep apnoea syndrome (OSAS) in ankylosing spondylitis (AS) patients. The prevalence of OSAS in AS patients is higher than reported in the general population. O.Salak. Rheumatology. February 17, 2009. (Also see: Ankylosing Spondylitis and Sleep Apnea) |
| Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7 (TLR7). These findings suggest that induction of TLR7 tolerance might be a new therapeutic approach to subdue inflammation in autoimmune diseases. T. Hayashi. PNAS. February 2, 2009. (Also see: Treating Autoimmunity) |
| Hidden Cost of Rheumatoid Arthritis (RA): Estimating Cost of Comorbid Cardiovascular Disease (CVD) and Depression Among Patients with RA. A significant proportion (13.4%) of patients with prevalent RA have comorbid CVD and/or depression, significantly affecting annual healthcare costs. A. Joyce. J. Rheum. February 17, 2009. (Also see: Rheumatoid Arthritis) |
